February 22,
2012
Dear Dick,
As a reminder, two
global research studies, called the elm•pc studies, are seeking men with
metastatic castration-resistant prostate cancer to participate in the effort to
evaluate a new investigational oral medication, TAK-700, given with
prednisone.
The studies will help determine if TAK-700, given with
prednisone, can lengthen the lives of men with metastatic castration-resistant
prostate cancer compared to prednisone alone.
Men enrolled in either study will be
assigned to one of two groups: those who will receive the investigational oral
medication, TAK-700, with prednisone, and those who will be treated with
prednisone alone. Prednisone is asteroid commonly used to treat advanced
prostate cancer.
TAK-700, an investigational oral lyase inhibitor, is
being studied for individuals with metastatic prostate cancer.
The elm•pc
studies are being conducted by Millennium: The Takeda Oncology Company.
To learn more about the elm•pc studies call 1-855-493-5672 or visit www.elmpctrials.com.
Please feel free to
forward this message along to other men you know who are dealing with painful
prostate cancer, or to physicians who might be interested in sharing the
information with their other patients. Thank you in advance for your
consideration and participation.
|
|
No comments:
Post a Comment